Vis enkel innførsel

dc.contributor.authorBraga, Tarcio Teodoro
dc.contributor.authorForni, Maria Fernanda
dc.contributor.authorCorrea-Costa, Matheus
dc.contributor.authorRamos, Rodrigo Nalio
dc.contributor.authorBarbuto, Jose Alexandre
dc.contributor.authorBranco, Paola
dc.contributor.authorCastoldi, Angela
dc.contributor.authorHiyane, Meire Ioshie
dc.contributor.authorDavanso, Mariana Rodrigues
dc.contributor.authorLatz, Eicke
dc.contributor.authorFranklin, Bernardo S.
dc.contributor.authorKowaltowski, Alicia J.
dc.contributor.authorCamara, Niels Olsen Saraiva
dc.date.accessioned2018-03-06T09:44:32Z
dc.date.available2018-03-06T09:44:32Z
dc.date.created2017-07-30T16:54:16Z
dc.date.issued2017
dc.identifier.citationScientific Reports. 2017, 7:39884, 1-14.nb_NO
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11250/2488819
dc.description.abstractUric acid is a damage-associated molecular pattern (DAMP), released from ischemic tissues and dying cells which, when crystalized, is able to activate the NLRP3 inflammasome. Soluble uric acid (sUA) is found in high concentrations in the serum of great apes, and even higher in some diseases, before the appearance of crystals. In the present study, we sought to investigate whether uric acid, in the soluble form, could also activate the NLRP3 inflammasome and induce the production of IL-1β. We monitored ROS, mitochondrial area and respiratory parameters from macrophages following sUA stimulus. We observed that sUA is released in a hypoxic environment and is able to induce IL-1β release. This process is followed by production of mitochondrial ROS, ASC speck formation and caspase-1 activation. Nlrp3−/− macrophages presented a protected redox state, increased maximum and reserve oxygen consumption ratio (OCR) and higher VDAC protein levels when compared to WT and Myd88−/− cells. Using a disease model characterized by increased sUA levels, we observed a correlation between sUA, inflammasome activation and fibrosis. These findings suggest sUA activates the NLRP3 inflammasome. We propose that future therapeutic strategies for renal fibrosis should include strategies that block sUA or inhibit its recognition by phagocytes.nb_NO
dc.language.isoengnb_NO
dc.publisherSpringer Naturenb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSoluble Uric Acid Activates the NLRP3 Inflammasomenb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber1-14nb_NO
dc.source.volume7:39884nb_NO
dc.source.journalScientific Reportsnb_NO
dc.identifier.doi10.1038/srep39884
dc.identifier.cristin1483408
dc.relation.projectNorges forskningsråd: 223255nb_NO
dc.description.localcode© The Author(s) 2017. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/nb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal